See more : Cannabix Technologies Inc. (BLO.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Novozymes A/S (NVZMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novozymes A/S, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Vaibhav Global Limited (VAIBHAVGBL.NS) Income Statement Analysis – Financial Results
- Sectra AB (publ) (SECT-B.ST) Income Statement Analysis – Financial Results
- Genimous Technology Co., Ltd. (000676.SZ) Income Statement Analysis – Financial Results
- Old Mutual Limited (OMU.L) Income Statement Analysis – Financial Results
- York Exports Limited (YORKEXP.BO) Income Statement Analysis – Financial Results
Novozymes A/S (NVZMY)
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.90B | 17.55B | 14.95B | 14.01B | 14.37B | 14.39B | 14.53B | 14.14B | 14.00B | 12.46B | 11.75B | 11.23B | 10.51B | 9.72B | 8.45B | 8.15B | 7.44B | 6.80B | 6.28B | 6.02B | 5.80B | 5.64B |
| Cost of Revenue | 8.18B | 7.98B | 6.33B | 6.16B | 6.42B | 6.14B | 6.12B | 6.02B | 5.87B | 5.31B | 5.03B | 4.81B | 4.60B | 4.31B | 3.75B | 3.79B | 3.49B | 3.15B | 2.94B | 2.85B | 2.80B | 2.73B |
| Gross Profit | 9.72B | 9.58B | 8.62B | 7.85B | 7.95B | 8.26B | 8.41B | 8.13B | 8.13B | 7.15B | 6.72B | 6.42B | 5.91B | 5.41B | 4.70B | 4.36B | 3.95B | 3.66B | 3.35B | 3.18B | 3.00B | 2.91B |
| Gross Profit Ratio | 54.32% | 54.56% | 57.68% | 56.04% | 55.34% | 57.37% | 57.90% | 57.46% | 58.06% | 57.38% | 57.18% | 57.17% | 56.21% | 55.66% | 55.63% | 53.51% | 53.09% | 53.73% | 53.26% | 52.77% | 51.77% | 51.54% |
| Research & Development | 2.02B | 2.00B | 2.01B | 1.94B | 1.97B | 1.87B | 1.91B | 1.87B | 1.90B | 1.84B | 1.53B | 1.53B | 1.46B | 1.36B | 1.21B | 1.10B | 995.00M | 880.00M | 793.00M | 775.00M | 749.00M | 713.00M |
| General & Administrative | 959.00M | 952.00M | 859.00M | 739.00M | 838.00M | 792.00M | 831.00M | 810.00M | 876.00M | 857.00M | 824.00M | 808.00M | 778.00M | 762.00M | 751.00M | 745.00M | 675.00M | 650.00M | 632.00M | 595.00M | 587.00M | 575.00M |
| Selling & Marketing | 2.37B | 2.27B | 1.94B | 1.58B | 1.63B | 1.57B | 1.62B | 1.62B | 1.57B | 1.41B | 1.48B | 1.42B | 1.38B | 1.24B | 1.12B | 1.06B | 921.00M | 844.00M | 748.00M | 750.00M | 730.00M | 729.00M |
| SG&A | 3.32B | 3.22B | 2.80B | 2.32B | 2.47B | 2.36B | 2.45B | 2.43B | 2.45B | 2.26B | 2.30B | 2.23B | 2.15B | 2.00B | 1.87B | 1.81B | 1.60B | 1.49B | 1.38B | 1.35B | 1.32B | 1.30B |
| Other Expenses | 405.00M | -75.00M | -66.00M | -14.00M | -26.00M | -43.00M | -63.00M | -117.00M | -98.00M | -102.00M | -13.00M | 9.00M | -50.00M | -69.00M | -64.00M | -47.00M | -123.00M | -59.00M | -34.00M | -31.00M | -44.00M | -56.00M |
| Operating Expenses | 5.75B | 5.15B | 4.74B | 4.24B | 4.41B | 4.19B | 4.30B | 4.18B | 4.25B | 4.00B | 3.82B | 3.68B | 3.57B | 3.30B | 3.01B | 2.86B | 2.47B | 2.32B | 2.14B | 2.09B | 2.02B | 1.96B |
| Cost & Expenses | 13.92B | 13.13B | 11.07B | 10.40B | 10.83B | 10.32B | 10.42B | 10.20B | 10.12B | 9.31B | 8.85B | 8.49B | 8.17B | 7.61B | 6.76B | 6.64B | 5.96B | 5.46B | 5.08B | 4.93B | 4.82B | 4.70B |
| Interest Income | 24.00M | 18.00M | 18.00M | 10.00M | 90.00M | 10.00M | 7.00M | 5.00M | 4.00M | 9.00M | 5.00M | 13.00M | 208.00M | 113.00M | 153.00M | 263.00M | 130.00M | 134.00M | 76.00M | 89.00M | 223.00M | 131.00M |
| Interest Expense | 173.00M | 102.00M | 102.00M | 63.00M | 86.00M | 13.00M | 27.00M | 31.00M | 31.00M | 58.00M | 66.00M | 74.00M | 133.00M | 107.00M | 220.00M | 348.00M | 226.00M | 256.00M | 132.00M | 98.00M | 190.00M | 178.00M |
| Depreciation & Amortization | 1.39B | 1.46B | 1.37B | 1.23B | 1.17B | 1.01B | 1.04B | 974.00M | 953.00M | 866.00M | 738.00M | 703.00M | 208.00M | 113.00M | 564.00M | 556.00M | 490.00M | 469.00M | 462.00M | 519.00M | 523.00M | 532.00M |
| EBITDA | 5.47B | 6.12B | 5.20B | 4.85B | 5.07B | 5.04B | 5.19B | 4.89B | 4.77B | 4.20B | 3.56B | 3.36B | 2.55B | 2.23B | 2.41B | 2.32B | 2.10B | 1.94B | 1.74B | 1.67B | 1.73B | 1.61B |
| EBITDA Ratio | 30.57% | 34.60% | 34.76% | 34.26% | 32.84% | 34.60% | 35.74% | 34.36% | 34.08% | 31.73% | 29.86% | 29.92% | 24.24% | 22.93% | 28.47% | 28.52% | 28.25% | 10.92% | 27.77% | 28.19% | 29.78% | 28.54% |
| Operating Income | 3.98B | 4.63B | 4.01B | 3.65B | 4.04B | 4.07B | 4.05B | 3.95B | 3.88B | 3.38B | 2.90B | 2.75B | 2.34B | 2.12B | 1.69B | 1.50B | 1.48B | 1.34B | 1.21B | 1.09B | 982.00M | 947.00M |
| Operating Income Ratio | 22.21% | 26.37% | 26.80% | 26.06% | 28.10% | 28.28% | 27.85% | 27.90% | 27.74% | 27.16% | 24.70% | 24.43% | 22.26% | 21.77% | 19.98% | 18.46% | 19.91% | 19.70% | 19.20% | 18.09% | 16.92% | 16.78% |
| Total Other Income/Expenses | -67.00M | -73.00M | -83.00M | -131.00M | -240.00M | -134.00M | -171.00M | -65.00M | -263.00M | -105.00M | -142.00M | -161.00M | 75.00M | 6.00M | -67.00M | -85.00M | -96.00M | -122.00M | -56.00M | -33.00M | 33.00M | -47.00M |
| Income Before Tax | 3.91B | 4.56B | 3.92B | 3.52B | 3.80B | 3.94B | 3.88B | 3.88B | 3.62B | 3.28B | 2.76B | 2.58B | 2.42B | 2.12B | 1.62B | 1.42B | 1.39B | 18.00M | 1.15B | 1.08B | 1.02B | 900.00M |
| Income Before Tax Ratio | 21.84% | 25.96% | 26.25% | 25.13% | 26.43% | 27.35% | 26.67% | 27.44% | 25.86% | 26.32% | 23.49% | 23.00% | 22.98% | 21.83% | 19.19% | 17.42% | 18.62% | 0.26% | 18.31% | 17.94% | 17.49% | 15.95% |
| Income Tax Expense | 870.00M | 870.00M | 779.00M | 695.00M | 644.00M | 709.00M | 756.00M | 831.00M | 796.00M | 754.00M | 558.00M | 568.00M | 587.00M | 509.00M | 427.00M | 357.00M | 343.00M | -307.00M | 289.00M | 288.00M | 280.00M | 253.00M |
| Net Income | 3.02B | 3.68B | 3.15B | 2.83B | 3.15B | 3.23B | 3.12B | 3.05B | 2.82B | 2.53B | 2.20B | 2.02B | 1.83B | 1.61B | 1.19B | 1.06B | 1.04B | 911.00M | 861.00M | 793.00M | 735.00M | 647.00M |
| Net Income Ratio | 16.89% | 20.94% | 21.04% | 20.16% | 21.94% | 22.42% | 21.46% | 21.57% | 20.16% | 20.27% | 18.73% | 17.94% | 17.39% | 16.60% | 14.13% | 13.04% | 14.01% | 13.39% | 13.71% | 13.16% | 12.67% | 11.47% |
| EPS | 10.88 | 13.29 | 11.32 | 10.07 | 11.06 | 11.11 | 10.56 | 10.15 | 9.23 | 8.10 | 7.01 | 6.42 | 5.80 | 5.15 | 3.85 | 3.43 | 3.37 | 2.90 | 2.63 | 2.32 | 2.09 | 1.79 |
| EPS Diluted | 10.88 | 13.19 | 11.23 | 10.02 | 11.01 | 11.03 | 10.49 | 10.06 | 9.12 | 8.02 | 6.93 | 6.33 | 5.71 | 5.05 | 3.79 | 3.37 | 3.28 | 2.82 | 2.57 | 2.27 | 2.07 | 1.78 |
| Weighted Avg Shares Out | 277.94M | 276.64M | 277.92M | 280.43M | 285.11M | 290.42M | 295.34M | 300.47M | 306.00M | 311.90M | 313.76M | 313.98M | 315.16M | 313.18M | 310.27M | 309.35M | 309.57M | 314.37M | 327.31M | 341.38M | 352.30M | 361.68M |
| Weighted Avg Shares Out (Dil) | 277.87M | 278.73M | 280.23M | 282.02M | 286.55M | 292.36M | 297.20M | 303.12M | 309.37M | 315.08M | 317.41M | 318.28M | 319.96M | 319.38M | 315.36M | 315.01M | 318.12M | 322.52M | 335.34M | 349.25M | 354.33M | 362.80M |
Transactions under Novozymes' stock buyback program
ICL vs. NVZMY: Which Stock Is the Better Value Option?
Transactions under Novozymes' stock buyback program
ICL vs. NVZMY: Which Stock Should Value Investors Buy Now?
ICL or NVZMY: Which Is the Better Value Stock Right Now?
Transactions under Novozymes' stock buyback program
Transactions under Novozymes' stock buyback program
Transactions under Novozymes' stock buyback program
Transactions under Novozymes' stock buyback program
AXTA vs. NVZMY: Which Stock Should Value Investors Buy Now?
Source: https://incomestatements.info
Category: Stock Reports